Cholic acid

(Cholbam®)

Cholbam®

Drug updated on 10/31/2024

Dosage FormCapsule (oral; 50 mg, 250 mg)
Drug ClassBile acids
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of bile acid synthesis disorders due to single enzyme defects (SEDs)
  • Indicated for adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
  • Association with Gestational Diabetes Mellitus (GDM) Risk: Cholic acid (CA) is identified as one of eight plasma bile acid metabolites associated with the risk of GDM during pregnancy. Taurocholic acid (TCA) is positively associated with GDM (Odds Ratio, OR 2.07, 95% Confidence Interval, CI [1.05, 3.96], P = 0.030), while lithocholic acid (LCA) shows a negative association (OR 0.83, 95% CI [0.68, 1.01], P = 0.065).
  • Population Focus: The study exclusively involves pregnant women, investigating the association of specific bile acids with the risk of developing GDM but does not provide information on cholic acid’s effectiveness as a treatment.
  • There is no safety information available in the reviewed studies.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Cholbam (cholic acid) Prescribing Information.2024Mirum Pharmaceuticals, Inc., Foster City, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
EASL Clinical Practice Guidelines on genetic cholestatic liver diseases2024Journal of Hepatology